Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 May;109(1):148–156. doi: 10.1111/j.1476-5381.1993.tb13545.x

Role of angiotensin AT1 and AT2 receptors in mediating the renal effects of angiotensin II in the anaesthetized dog.

K L Clark 1, M J Robertson 1, G M Drew 1
PMCID: PMC2175586  PMID: 8495237

Abstract

1. Experiments were performed using the selective AT1 receptor antagonist, GR117289, and the selective AT2 receptor antagonist, PD123177, to assess the relative importance of AT1 versus AT2 receptors in mediating the renal effects of angiotensin II (AII) in vivo, in salt-replete pentobarbitone-anaesthetized dogs. 2. The AT1 receptor antagonist, GR117289 (0.5 mg kg-1 + 1 microgram kg-1 min-1, i.v.), caused renal vasodilatation, characterized by a mean increase of 21 +/- 5% in renal blood flow, 45 min post-dose. GR117289 also caused a fall in mean blood pressure (12 +/- 4%), but despite this, sodium and urine excretion were not reduced. Indeed, there was a tendency for urine output and sodium excretion to increase, although the changes were not statistically significant. GR117289 caused a reduction in plasma aldosterone levels (-35 +/- 16%) 45 min post-dose, despite increasing plasma renin activity (+ 173 +/- 42%). In contrast to GR117289, the AT2 receptor antagonist, PD123177 (20 micrograms kg-1 min-1 intra-renal artery; i.r.a.) caused no significant change in blood pressure, renal blood flow, or sodium and urine excretion, indicating that the renal effects of endogenous AII in these salt-replete animals are mediated predominantly by AT1 receptors. 3. Intra-renal artery infusion of AII (1-300 ng kg-1 min-1) caused dose-related renal vasoconstriction, and decreases in urine output, sodium excretion, fractional excretion of sodium, and glomerular filtration rate (GFR).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
156

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Batin P., Gardiner S. M., Compton A. M., Bennett T. Differential regional haemodynamic effects of the non-peptide angiotensin II antagonist, DuP 753, in water-replete and water-deprived Brattleboro rats. Life Sci. 1991;48(8):733–739. doi: 10.1016/0024-3205(91)90087-r. [DOI] [PubMed] [Google Scholar]
  2. Bumpus F. M., Catt K. J., Chiu A. T., DeGasparo M., Goodfriend T., Husain A., Peach M. J., Taylor D. G., Jr, Timmermans P. B. Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension. 1991 May;17(5):720–721. doi: 10.1161/01.hyp.17.5.720. [DOI] [PubMed] [Google Scholar]
  3. Chang R. S., Lotti V. J. Angiotensin receptor subtypes in rat, rabbit and monkey tissues: relative distribution and species dependency. Life Sci. 1991;49(20):1485–1490. doi: 10.1016/0024-3205(91)90048-g. [DOI] [PubMed] [Google Scholar]
  4. Chiu A. T., Herblin W. F., McCall D. E., Ardecky R. J., Carini D. J., Duncia J. V., Pease L. J., Wong P. C., Wexler R. R., Johnson A. L. Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun. 1989 Nov 30;165(1):196–203. doi: 10.1016/0006-291x(89)91054-1. [DOI] [PubMed] [Google Scholar]
  5. Chiu A. T., McCall D. E., Price W. A., Wong P. C., Carini D. J., Duncia J. V., Wexler R. R., Yoo S. E., Johnson A. L., Timmermans P. B. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990 Feb;252(2):711–718. [PubMed] [Google Scholar]
  6. Cogan M. G. Angiotensin II: a powerful controller of sodium transport in the early proximal tubule. Hypertension. 1990 May;15(5):451–458. doi: 10.1161/01.hyp.15.5.451. [DOI] [PubMed] [Google Scholar]
  7. Douglas J. G. Angiotensin receptor subtypes of the kidney cortex. Am J Physiol. 1987 Jul;253(1 Pt 2):F1–F7. doi: 10.1152/ajprenal.1987.253.1.F1. [DOI] [PubMed] [Google Scholar]
  8. Edwards R. M., Stack E. J., Weidley E. F., Aiyar N., Keenan R. M., Hill D. T., Weinstock J. Characterization of renal angiotensin II receptors using subtype selective antagonists. J Pharmacol Exp Ther. 1992 Mar;260(3):933–938. [PubMed] [Google Scholar]
  9. Fenoy F. J., Milicic I., Smith R. D., Wong P. C., Timmermans P. B., Roman R. Effects of DuP 753 on renal function of normotensive and spontaneously hypertensive rats. Am J Hypertens. 1991 Apr;4(4 Pt 2):321S–326S. doi: 10.1093/ajh/4.4.321s. [DOI] [PubMed] [Google Scholar]
  10. Gibson R. E., Thorpe H. H., Cartwright M. E., Frank J. D., Schorn T. W., Bunting P. B., Siegl P. K. Angiotensin II receptor subtypes in renal cortex of rats and rhesus monkeys. Am J Physiol. 1991 Sep;261(3 Pt 2):F512–F518. doi: 10.1152/ajprenal.1991.261.3.F512. [DOI] [PubMed] [Google Scholar]
  11. Gröne H. J., Simon M., Fuchs E. Autoradiographic characterization of angiotensin receptor subtypes in fetal and adult human kidney. Am J Physiol. 1992 Feb;262(2 Pt 2):F326–F331. doi: 10.1152/ajprenal.1992.262.2.F326. [DOI] [PubMed] [Google Scholar]
  12. Harris P. J. Regulation of proximal tubule function by angiotensin. Clin Exp Pharmacol Physiol. 1992 Apr;19(4):213–222. doi: 10.1111/j.1440-1681.1992.tb00441.x. [DOI] [PubMed] [Google Scholar]
  13. Laragh J. H. New angiotensin converting enzyme inhibitors. Their role in the management of hypertension. Am J Hypertens. 1990 Nov;3(11):257S–265S. doi: 10.1093/ajh/3.11s.257s. [DOI] [PubMed] [Google Scholar]
  14. Lohmeier T. E., Cowley A. W., Jr, Trippodo N. C., Hall J. E., Guyton A. C. Effects of endogenous angiotensin II on renal sodium excretion and renal hemodynamics. Am J Physiol. 1977 Nov;233(5):F388–F395. doi: 10.1152/ajprenal.1977.233.5.F388. [DOI] [PubMed] [Google Scholar]
  15. Navar L. G., Saccomani G., Mitchell K. D. Synergistic intrarenal actions of angiotensin on tubular reabsorption and renal hemodynamics. Am J Hypertens. 1991 Jan;4(1 Pt 1):90–96. doi: 10.1093/ajh/4.1.90. [DOI] [PubMed] [Google Scholar]
  16. Robertson M. J., Barnes J. C., Drew G. M., Clark K. L., Marshall F. H., Michel A., Middlemiss D., Ross B. C., Scopes D., Dowle M. D. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist. Br J Pharmacol. 1992 Dec;107(4):1173–1180. doi: 10.1111/j.1476-5381.1992.tb13425.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Schmid H. E., Jr Renal autoregulation and renin release during changes in renal perfusion pressure. Am J Physiol. 1972 May;222(5):1132–1137. doi: 10.1152/ajplegacy.1972.222.5.1132. [DOI] [PubMed] [Google Scholar]
  18. Schmidt M., Krieger J. P., Devissaguet M., Imbs J. L. Renal effects of perindoprilat, an angiotensin-converting enzyme inhibitor, in the anesthetized dog. J Cardiovasc Pharmacol. 1989 Feb;13(2):283–290. doi: 10.1097/00005344-198902000-00017. [DOI] [PubMed] [Google Scholar]
  19. Sechi L. A., Grady E. F., Griffin C. A., Kalinyak J. E., Schambelan M. Characterization of angiotensin II receptor subtypes in the rat kidney and heart using the non-peptide antagonists DuP 753 and PD 123 177. J Hypertens Suppl. 1991 Dec;9(6):S224–S225. [PubMed] [Google Scholar]
  20. Whitebread S., Mele M., Kamber B., de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun. 1989 Aug 30;163(1):284–291. doi: 10.1016/0006-291x(89)92133-5. [DOI] [PubMed] [Google Scholar]
  21. Widdop R. E., Gardiner S. M., Kemp P. A., Bennett T. Inhibition of the haemodynamic effects of angiotensin II in conscious rats by AT2-receptor antagonists given after the AT1-receptor antagonist, EXP 3174. Br J Pharmacol. 1992 Nov;107(3):873–880. doi: 10.1111/j.1476-5381.1992.tb14540.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wong P. C., Hart S. D., Duncia J. V., Timmermans P. B. Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs. Eur J Pharmacol. 1991 Sep 24;202(3):323–330. doi: 10.1016/0014-2999(91)90274-t. [DOI] [PubMed] [Google Scholar]
  23. Wong P. C., Hart S. D., Timmermans P. B. Effect of angiotensin II antagonism on canine renal sympathetic nerve function. Hypertension. 1991 Jun;17(6 Pt 2):1127–1134. doi: 10.1161/01.hyp.17.6.1127. [DOI] [PubMed] [Google Scholar]
  24. Wong P. C., Hart S. D., Zaspel A. M., Chiu A. T., Ardecky R. J., Smith R. D., Timmermans P. B. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2). J Pharmacol Exp Ther. 1990 Nov;255(2):584–592. [PubMed] [Google Scholar]
  25. Xie M. H., Liu F. Y., Wong P. C., Timmermans P. B., Cogan M. G. Proximal nephron and renal effects of DuP 753, a nonpeptide angiotensin II receptor antagonist. Kidney Int. 1990 Sep;38(3):473–479. doi: 10.1038/ki.1990.228. [DOI] [PubMed] [Google Scholar]
  26. Zarahn E. D., Ye X., Ades A. M., Reagan L. P., Fluharty S. J. Angiotensin-induced cyclic GMP production is mediated by multiple receptor subtypes and nitric oxide in N1E-115 neuroblastoma cells. J Neurochem. 1992 May;58(5):1960–1963. doi: 10.1111/j.1471-4159.1992.tb10076.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES